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1165-133 Basal Respiratory Exchange Ratio Is Altered With Statin 
Use in Normals
Colin T. Phillips, Nancy L. Gray, Lyn M. Puhek, Frederich G. McDonald, Michael J. 
Sullivan, Paul S. Phillips, Scripps Mercy Hospital, San Diego, CA, University of 
Washington, Seattle, WA
Background: Statin therapy is prescribed for increasing numbers of patients. Previous
work in statin myotoxicity has suggested a defect in fatty acid oxidation. The fasting respi-
ratory exchange ratio (RER) provides a means to identify substrate use. This project
assesses aerobic function and substrate utilization on statin therapy using cardiopulmo-
nary exercise testing. 
Methods: Six normal control volunteers performed two identical exercise regimens six
weeks apart while fasting on and off statins. The Orca® cardiopulmonary exercise testing
system was calibrated to a known gas mixture before each test. The protocol consisted
of 30 minutes of rest followed by 8 minutes of ramped exercise. Peak oxygen consump-
tion (VO2 max), anaerobic threshold (AT), ventilatory efficiency (VE / VCO2) and param-
eters of fuel selection, including basal RER, and the change in RER between rest and
early exercise (∆ RER) were recorded.
Results: A summary of the results is in the table below. 
There was no change in VO2 max, AT, or VE/VCO2 for the subjects on statins. The basal 
RER was significantly increased on statin therapy († p=0.0001). The ∆ RER also demon-
strated significant change on statin therapy (‡ p=0.03).
Conclusions: While there was no change in aerobic function on statin therapy, parame-
ters of fuel selection (fasting RER and ∆ RER) both increased. This suggests an alter-
ation in fatty acid oxidation related to statin therapy in normals.
1165-134 Can Electrical Muscle Stimulation of the Legs Produce 
Cardiovascular Exercise?
Prithwish Banerjee, Brian Caulfield, Louis Crowe, Andrew L. Clark, Castle Hill Hospital, 
Hull, United Kingdom, University College Dublin, Dublin, Ireland
Background: Despite its well-known benefits, not everybody is able to undertake physical
exercise due to limitations related to their underlying disease (heart failure, obesity etc) or
orthopedic/joint problems. New techniques of producing cardiovascular exercise are
therefore required that do not involve physical exertion. This study was carried out to
investigate a new method of facilitating cardiovascular exercise using electrical muscle
stimulation (EMS) of leg muscles.
Methods: Ten healthy volunteers completed 4 EMS training sessions using a hand held,
battery operated EMS device. The stimuli were delivered to the quadriceps, hamstring
and glutei muscles via appropriately placed silicon rubber electrodes incorporated into a
pair of tight fitting shorts. At each session subjects completed 3 minutes of stimulation at
each of 4 stimulation outputs (10%, 20%, 30% & 40% of maximum output) whilst cardiop-
ulmonary gas exchange was measured. Physiological responses and comfort levels at
increasing levels of stimulation as well as reproducibility of effect were evaluated.
Results: Subjects included 8 males and 2 females with mean age 37.6 ± 6.8 years. Sub-
jects achieved steady state at each level of stimulation with a significant increase in phys-
iological response at successive levels (P<0.0001). Group average heart rate and VO2 at
40% stimulation intensity were 101± 12 BPM and 14.9±4.3 ml/kg/min respectively. At
stimulation level of 40% output VO2, VCO2, VE and heart rate increased by 0.69 ± 0.2 L/
min, 0.63 ± 0.2 L/min, 13.8 ± 10.8 L/min and 30.1 ± 11.1BPM respectively above resting
values. Subjects reported mild discomfort, which improved at successive sessions and
demonstrated good reproducibility of effect from session to session.
Conclusion: These results demonstrate that this method of EMS is capable of producing
a physiological response consistent with cardiovascular exercise. The stimulation was
well tolerated by the subjects and there was good reproducibility of effect. Results will be
discussed in detail.
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856-1 Mechanical Circulatory Support: Evolving Trends in 
Support Duration
Tofy Mussivand, University of Ottawa Heart Institute, Ottawa, ON, Canada
BACKGROUND: There are increasing anecdotal reports of mechanical circulatory sup-
port patients being supported for longer durations. In addition, there have been changes
to the waiting list status of device recipients implemented by both UNOS (United Network
for Organ Sharing) and Eurotransplant. Furthermore, clinical views regarding optimal
transplant timing for device recipients have also evolved (e.g. early experience favored
rapid transplantation). To assess the impact of these factors, support durations over the
last decade were studied utilizing a large dataset from a single device (Novacor LVAS).
METHODS: The international dataset consisted of all patients implanted with the Nova-
cor LVAS from January 1991 through December 2001 (n=1235). Mean support durations
were calculated for each year of the study period. Support durations were also calculated
for survivors versus non-survivors. Results were tested for statistical significance using
Pearson’s correlation coefficient.
RESULTS: Mean support duration for all recipients increased from 32 days in 1991 to
196 days in 2002. For the survivors (i.e. those currently supported, transplanted or
weaned), mean support times increased from 40 days in 1991 to 284 days in 2001.
There was a strong linear correlation for both of these groups, R2=0.972 (p < 0.0001) and
R2=0.980 (p < 0.0001), respectively. In terms of the non-survivors (n=513), the mean
support duration rose from 26 days in 1991 to 104 days in 1995 and since that time has
remained essentially flat at approximately 100 days, whereas the survivors mean dura-
tion continues to increase steadily.
CONCLUSION: 1) Mean support duration for device recipients has increased six-fold
during the decade of study. 2) Considering this evolving trend in support duration greater
emphasis should be placed on the use of totally implantable devices that permit potential
patient hospital discharge.
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856-2 Cardiac Recovery During Left Ventricular Assist Device 
Support: Results From the LVAD Working Group
Simon Maybaum, O. H. Frazier, Randall Starling, Leslie Miller, Srinivas Murali, Keith 
Aaronson, Kenneth Margulies, Steve Xydas, Susan McRee, Guillermo Torre, The LVAD 
Working Group, Columbia University, New York, NY
Background: Some heart failure (HF) patients supported with a left ventricular assist
device (LVAD) demonstrate sufficient cardiac recovery to undergo LVAD explantation.
The LVAD Working Group is a multi-center prospective study of cardiac function during
LVAD support. Our aim is to define the rate, time course and durability of recovery and to
seek markers that might identify explantation candidates.
Methods: Patients undergo monthly evaluation during LVAD support, including echocar-
diography at full and reduced (4 L/min) LVAD flow and cardiopulmonary exercise testing.
Dobutamine echocardiography with hemodynamic measurements are performed in
patients demonstrating improvement in resting function.
Results: 64 patients with HF for 58 ± 70 months underwent LVAD implantation during the
14 months of the study. Duration of LVAD support was 165.6 ± 85 days. 32 patients
(50%) have been transplanted, 6 have expired (9.4%) and 23 patients remain on LVAD
support. After 30 days of support as compared to pre-LVAD, there was significant
improvement in left ventricular (LV) ejection fraction (16.6 ± 6.9 vs 35.4 ± 14.1 %,
p<.00001) and reduction in LV end diastolic diameter (7.2 ± 1.2 vs 4.8 ± 1.0 cm,
p<.00001) and LV mass (321 ± 118 vs 198 ± 82 g, p<.00001). 36% of patients had LVEF
> 40% with device flow reduced to 4 L/min. LVEF peaked at 30 days and then plateaued,
while LV mass progressively decreased with time. No significant differences were seen
between ischemic (44%) and non-ischemic (56%) patients. With longer periods of sup-
port, there was significant improvement in peak oxygen consumption (13.4 ± 4.1 vs 19.1
± 6.4 ml/kg/min, 30 vs 120 days, p<.01). Thirteen patients with improvement in resting
function underwent hemodynamic stress testing and 3 patients with acute HF (< 8 days)
underwent explantation and have normal LV function 20-27 weeks post-explant. No
patients with chronic HF underwent LVAD explantation.
Conclusions: This is the first large prospective study of cardiac function during LVAD
support. Our results suggest that LV function improves, but that the degree of recovery is
insufficient for device explantation in patients with chronic HF. The addition of novel med-
ical therapies may modify these results.
N RER 
off 
statins
RER 
on 
statins
∆ RER*
off 
statins
∆ RER* 
on 
statins
VO2 
max 
off 
statins
ml/min/
kg
VO2 
max 
on 
statins
ml/min/
kg
AT 
off 
statins
ml/min/
kg
AT
on 
statins
ml/min/
kg
∆ VE / ∆ 
VCO2
off statins
∆ VE / ∆ 
VCO2
on statins
6 0.76 ± 
0.03 †
0.86 ± 
0.06 †
0.03 ± 
0.04 ‡
0.07 ± 
0.03 ‡
37 ±13 37 ± 13 27 ± 7 25 ± 12 25 ± 4 25 ± 3
